Peptide Therapies/August 15, 2026/2 min read

GLP-1 Drugs in Type 1 Diabetes: Learning from Daily Injections to Weekly Options

Researchers have been studying GLP-1 receptor agonists as an add-on treatment for Type 1 diabetes. Here's what early trials revealed—and how the approach is evolving.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

peptidesGLP-1C-peptideimmunotherapyadjunct therapy

Key takeaways

Daily GLP-1 injections showed promise for improving blood sugar control and weight in Phase 2 and Phase 3 trials
Safety concerns emerged during these trials, including increased hypoglycemia and ketosis risk
The field is shifting toward weekly injectable versions with better personalized insulin dosing and continuous glucose monitoring guidance
Earlier trials used simpler, one-size-fits-all insulin adjustment rules that may not have been optimal

What Are GLP-1 Receptor Agonists?

Glucagon-like peptide-1 (GLP-1) receptor agonists are medications originally developed for Type 2 diabetes. Researchers became interested in testing whether they could also help people with Type 1 diabetes when used alongside insulin therapy. The early focus was on daily injectable versions of these drugs.

What the Early Trials Found

Phase 2 and Phase 3 clinical trials of daily GLP-1 injections showed encouraging results. When added to insulin, these drugs appeared to help improve blood sugar control and reduce weight. However, researchers also noticed safety signals that raised concerns: some participants experienced more frequent low blood sugar episodes (hypoglycemia) and a serious condition called ketosis.

Why Insulin Dosing Mattered

One factor that may have contributed to these safety issues was how insulin doses were adjusted during the trials. The researchers used straightforward, standardized rules that didn't account for individual differences. The trials also took place before continuous glucose monitoring (CGM) devices became widely available—technology that now helps people see their blood sugar patterns in real time and make more informed dosing decisions.

Where the Research Is Heading

Based on these learnings, the focus has shifted to weekly GLP-1 injections instead of daily ones. Researchers are now using more personalized approaches to insulin titration—meaning doses are tailored to each person rather than using a one-size-fits-all method. Additionally, newer trials are being guided by CGM data, which gives a clearer picture of how blood sugar responds to treatment changes.

Evidence label

Source: Endocrinology and metabolism clinics of North America. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.